What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence for anitocabtagene autoleucel (anito-cel) primarily comes from a single-arm Phase 2 trial (iMMagine-1) which reported a high overall response rate (ORR) of 96% and a complete response (CR) rate of 74%. However, there are no head-to-head comparisons against standard of care (SOC) available, and the ongoing Phase 3 trial (iMMagine-3) has not yet reported results. This limits the ability to claim superiority over existing treatments, thus justifying a B++ rating for comparable efficacy.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses or incremental cost-effectiveness ratios (ICERs) for anito-cel were found in the reviewed sources. The cost of the therapy is not yet known, and there are no economic models available, resulting in a C rating for cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
No health-related quality of life data for anito-cel were identified in the sources reviewed. Although HRQoL instruments are planned for use in the ongoing iMMagine-3 trial, results are not yet available. The absence of any publicly available HRQoL data leads to a C rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of anito-cel appears acceptable based on the iMMagine-1 trial data, which reported manageable adverse events with a low incidence of severe toxicities. The most common adverse events were CRS and ICANS, with a majority being grade 1 or 2. However, the absence of comparative safety data against SOC limits the overall assessment, justifying an A rating.
Was the drug compared against what payers expect? — Comparator Selection
The comparator selection for the iMMagine-3 trial includes established SOC regimens with robust phase 3 evidence. This alignment with current treatment practices supports a strong rating for comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient population in the iMMagine-1 trial is well-defined, including heavily pretreated patients with relapsed/refractory multiple myeloma. However, the exclusion of patients who have previously received BCMA-targeted therapies may limit generalizability, leading to a rating of A.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Anito-cel can be integrated into existing care pathways with some adjustments, such as the need for leukapheresis and specialized monitoring. The absence of a companion diagnostic requirement further supports its integration, justifying an A rating.
Are the wider system costs understood? — Resource Use and Cost Implications
No specific resource use or cost implications for anito-cel were identified in the reviewed sources. The lack of quantitative data on resource utilization leads to a C rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from sponsor-reported data from the iMMagine-1 trial, which is a single-arm study. While the data are explicit, the reliance on non-peer-reviewed sources and the absence of comparative data limit the robustness of the evidence, resulting in a B++ rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term outcomes and economic implications of anito-cel due to the lack of available data on cost-effectiveness, resource use, and broader system impacts. This leads to a C rating.
